CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Ambulatory models for autologous stem-cell transplantation: a systematic review of the health impact.
Ambulatory models for autologous stem-cell transplantation: a systematic review of the health impact.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自体干细胞移植(ASCT)是多发性骨髓瘤管理的标准治疗,在某些类型淋巴瘤的治疗中也具有确立的地位。过去几十年中,ASCT的实施数量显著增加,导致医疗服务压力和成本上升。传统的ASCT模式包括在手术的任何阶段将患者收入专门的移植病房。为了优化医疗服务提供,未来应重点关注门诊(门诊/居家)模式。因此,门诊ASCT模式能够减少平均住院时间和医疗服务压力,具有显著的节约成本优势以及高度的患者和照护者满意度。此外,它还为其他复杂操作如异基因移植或CAR-T 细胞治疗释放了床位资源。本系统综述旨在记录门诊/居家ASCT模式的健康影响、可行性和安全性,这些模式正在世界范围内越来越多地被应用。
Autologous stem-cell transplantation (ASCT) is the standard of care for the management of multiple myeloma and has a well-established role in the treatment of some types of lymphoma. Over the last decades, the number of ASCT performed has increased significantly, leading to elevated pressure and cost for healthcare services.
Conventional model of ASCT includes the admission of patients to a specialized Transplant Unit at any stage of the procedure. To optimize healthcare provision, ambulatory (outpatient/at-home) setting should be the focus moving forward.
Thus, ambulatory ASCT model permits reducing average hospital stays and pressures on healthcare services, with significant cost-saving benefits and high degree of patient and caregiver satisfaction.
In addition, it facilitates the bed resource for other complex procedures such as allografts or CAR-T cell therapy. The aim of this systematic review is to document the health impact, feasibility and safety of the outpatient/at-home ASCT models, which are increasingly being applied around the world.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。